Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services
Lucence Secures MolDX Approval for LiquidHALLMARK® ctDNA and ctRNA Liquid Biopsy Test to Advance Non-Invasive Cancer Diagnostics
Lucence Announces Expanded Access for LiquidHALLMARK® Liquid Biopsy Test Through Participation Across Regence Plans
Lucence and Diagnostics Development Hub (DxD Hub) Collaborate on Expanding Multi-Cancer Early Detection Testing to Alternative Sample Types
Lucence Confirms Comprehensive Medicare Coverage for LiquidHALLMARK® and Demonstrates Sensitive Detection of Lung Cancer Biomarkers in Prospective Study